RT Journal Article
SR Electronic
T1 Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.21250293
DO 10.1101/2021.01.22.21250293
A1 Nicholas C. Cullen
A1 Antoine Leuzy
A1 Shorena Janelidze
A1 Sebastian Palmqvist
A1 Anna L. Svenningsson
A1 Erik Stomrud
A1 Jeffrey L. Dage
A1 Niklas Mattsson-Carlgren
A1 Oskar Hansson
YR 2021
UL http://medrxiv.org/content/early/2021/01/22/2021.01.22.21250293.abstract
AB Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly indviduals. We therefore tested if plasma measurements of amyloid-β (Aβ)42/40, phospho-tau217 (P-tau217), and neurofilament light (NfL) together predict clinical deterioration in 435 CU individuals followed for an average of 4.8 ±1.7 years in the BioFINDER study. A combination of all three plasma biomarkers and basic demographics best predicted change in the cognition (Pre-Alzheimer’s Clinical Composite; R2=0.14, 95% CI [0.12-0.17]; P<0.0001) and subsequent AD dementia (AUC=0.82, 95% CI [0.77-0.91], P<0.0001). In a simulated clinical trial, a screening algorithm combining all three plasma biomarkers would reduce the required sample size by 70% (95% CI [54-81]; P<0.001) with cognition as trial endpoint, and by 63% (95% CI [53-70], P<0.001) with subsequent AD dementia as trial endpoint. Plasma ATN biomarkers show usefulness in cognitively unimpaired populations and could make large clinical trials more feasible and cost-effective.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01208675Funding StatementWork at the authors' research center supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383, and WCMM fellowship for Mattsson-Carlgren), the Medical Faculty at Lund University (WCMM fellowship for Mattsson-Carlgren), Region Skane (WCMM fellowship for Mattsson-Carlgren), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-745911, AF-930655), the Swedish Brain Foundation (FO2019-0326, FO2019-0029), The Parkinson foundation of Sweden (1280/20), the Skane University Hospital Foundation (2020-O000028), Regionalt Forskningsstod (2020-0314), the Swedish federal government under the ALF agreement (2018-Projekt0279), Stiftelsen Gamla Tjanarinnor (2019-00845), EU Joint Programme - Neurodegenerative Disease Research (2019-03401), The Bundy Academy, and The Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave written informed consent. Ethical approval was given by the Regional Ethical Committee in Lund, Sweden.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor more information visit Biofinder.se. Relevant data from the study and code to perform the statistical analysis herein may be made available upon request from qualified researchers.